rituximab,ibrutinib,Bendamustine
biogen,roche,janssen,abbvie,teva pharmaceuticals,novartis
['lymsm', 'rituximab', 'shine', 'lymphoma']
congress #asco22 | talks about the phase iii shine trial of ibrutinib + bendamustine-rituximab +r maintenance for pts with #mcl. n=523. median follow-up of 84.7 months. med pfs of 80.6 months ibr + br arm vs 52.9 mo in placebo +br #lymphoma #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm